K. Syrigos

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

John Souglakos, N. Androulakis, K. Syrigos et al. · British Journal of Cancer · 2006 · 403 citations · Full text

Medicine, Oncology, Pharmacology +15

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline

Anna Falanga, Cihan Ay, Marcello Di Nisio et al. · Annals of Oncology · 2023 · 384 citations · Full text

Medicine, Hematology, Oncology +14

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

G. Stathopoulos, K. Syrigos, Gerasimos Aravantinos et al. · British Journal of Cancer · 2006 · 196 citations · Full text

Medicine, Oncology, Pharmacology +14

Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery

D Alexiou, Anastasios J. Karayiannakis, K. Syrigos et al. · European Journal of Cancer · 2001 · 172 citations

Medicine, Oncology, Pathology +12

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer

Anna M. Kirby, Roger A’Hern, Consuelo D'Ambrosio et al. · British Journal of Cancer · 2006 · 100 citations · Full text

Medicine, Oncology, Pharmacology +13